The Effect of Breast Milk Odor on Pain Response and Salivary Cortisol Level in Preterm Infants

November 29, 2022 updated by: Taipei Medical University

The Effect of Breast Milk Odor on Pain Response and Salivary Cortisol Level Duration Heel Stick Procedure in Preterm Infants: A Randomized Controlled Trial

The aims of this randomized controlled trial are investigate the effects of breast milk odor on pain response and saliva cortisol level duration heel stick blood sampling in preterm infants. Partipants will randomly assigned into the experimental group (breast milk odor) or control group (distilled water odor). The Premature Infant Pain Profile-Revised (PIPP-R) and Salimetrics® Cortisol Enzyme Immunoassay Kit are used to measuring the pain response and saliva cortisol level.

Study Overview

Status

Not yet recruiting

Detailed Description

Preterm infants need to undergo more invasive medical interventions than full-term healthy newborns to maintain their lives. Physiological functions changes brought about by pain and stress stimulations may complicate nerve development in preterm infants. Therefore, providing positive sensory supportive interventions to reduce pain and stress is imperative for preterm infants. Studies have confirmed that the use of painkillers, breastfeeding, swaddling, kangaroo care, giving glucose or sucrose can help reduce pain. The sense of smell matures at 28 weeks of gestation age, and newborns can recognize the mother's smell after birth (Nishitani et al., 2009).

In recent years, several randomized studies have explored the effects of smell on reducing pain and stress in preterm infants, but the results are still inconclusive due to the lack of randomization blinding and a variety of smell interventions. It is desirable to plan a high-quality study. Although premature infants need to be separated from their mothers in nurseries due to medical needs, breast milk is still the best source of nutrition. The aims of this study are to investigate the effect of breast milk odor on pain response and saliva cortisol level duration heel stick blood sampling in preterm infants with gestation age at 30 to 37 weeks. A Randomized Controlled Trial will be designed. Preterm infants, who will receive heel sticks, are randomly assigned into the experimental group (breast milk odor) or control group (distilled water odor). The Premature Infant Pain Profile-Revised (PIPP-R) and Salimetrics® Cortisol Enzyme Immunoassay Kit are used to measuring the pain response and saliva cortisol level. Data will be analyzed by SPSS 22.0 (SPSS Inc., Chicago, IL, USA) using descriptive statistics, independent t-test, ANOVA, Generalized Estimating Equation linear multiple regression analysis… etc.

Study Type

Interventional

Enrollment (Anticipated)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 second to 1 week (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Premature babies whose gestational age is between 30 weeks to 36 weeks and six days, with a birth weight > 1000 grams.
  2. Apgar Score > 6 at 5 minutes of birth.
  3. Within 10 days of birth, the vital signs are stable.
  4. Those who have medical needs, such as blood monitoring of neonatal serum bilirubin, blood sugar, electrolyte, or neonatal screening, etc., need heel puncture blood sampling.

Exclusion Criteria:

  1. Those who have been diagnosed by a physician with severe congenital malformations, chromosomal abnormalities, respiratory distress, epilepsy, necrotizing enterocolitis, intracranial hemorrhage, periventricular leukomalacia, sepsis, meningitis, or hyperbilirubinemia.
  2. Those who have bronchopulmonary dysplasia or other chronic lung diseases that require the use of ventilator or non-invasive positive pressure respiratory support.
  3. Have used analgesics or anesthetics within 48 hours before giving the intervention of the study, or are participating in other studies that provide intervention for pain reduction.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Breast milk odor
Participants received breast milk odor before and during heel stick.

The intervention of the experimental group was to stimulate the odor of breast milk. The researchers informed the mothers of premature infants in advance on the day before the experiment, and collected the breast milk samples in the morning before eating on the day of the experiment (excluding the influence of the odor of breast milk by diet). The researchers took a clean cotton ball so that the breast milk was completely absorbed by the cotton ball, and placed the cotton ball that absorbed breast milk at a distance of 5cm next to the mouth and nose of the premature infant, so that the premature infant could receive the smell of breast milk.

The intervention of the control group was to stimulate the smell of distilled water.

Placebo Comparator: Placebo
Participants received placebo before and during heel stick.
Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in pain on PIPP-R(Premature Infant Pain Profile - Revised, PIPP-R) in experimental group and control group from baseline and the time during heel stick.
Time Frame: before heel stick [baseline] and during heel stick [5th minute].
PIPP-R is suitable for newborns from GA 25 to 41 weeks. The evaluation items include: two physiological indicators (heartbeat, blood oxygen), three behavioral indicators (frowning, closed eyes, facial expressions such as nasolabial folds), and two corrections factors (gestational weeks and behavioral status). Each item is scored on a scale of 0 to 3 on four scales. The full score varies according to the gestational week: 21 points up to 28 weeks, 20 points for 28 to 31+6 weeks, 19 points for 32 to 35+6 weeks, and 18 points for over 36 weeks. A total PIPP-R score of 6 or less indicates little or no pain, a score of 6 to 12 indicates mild to moderate pain, and a score greater than 12 indicates moderate to severe pain.
before heel stick [baseline] and during heel stick [5th minute].
Change in salivary cortisol in experimental group and control group from baseline to the time after heel stick.
Time Frame: before heel stick [baseline] and 25 minutes after heel stick [30th minute, reflecting pain and stress conditions at the moment of heel stick])
Salimetrics® Cortisol Enzyme Immunoassay Kit Analytical sensitivity .Salivary cortisol samples in neonatal detection range: not detected to 3.41μg/dL.
before heel stick [baseline] and 25 minutes after heel stick [30th minute, reflecting pain and stress conditions at the moment of heel stick])

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

December 1, 2022

Primary Completion (Anticipated)

September 1, 2023

Study Completion (Anticipated)

September 30, 2023

Study Registration Dates

First Submitted

September 20, 2022

First Submitted That Met QC Criteria

September 27, 2022

First Posted (Actual)

September 28, 2022

Study Record Updates

Last Update Posted (Actual)

December 1, 2022

Last Update Submitted That Met QC Criteria

November 29, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on Placebo

Subscribe